GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » Float Percentage Of Total Shares Outstanding

Relmada Therapeutics (STU:4E2) Float Percentage Of Total Shares Outstanding : 98.34% (As of Jun. 16, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Relmada Therapeutics's float shares is 29.67 Mil. Relmada Therapeutics's total shares outstanding is 30.17 Mil. Relmada Therapeutics's float percentage of total shares outstanding is 98.34%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Relmada Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Relmada Therapeutics's Institutional Ownership is 13.69%.

Relmada Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Relmada Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=29.67/30.17
=98.34%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relmada Therapeutics (STU:4E2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
HOWL MIRO ALDX NYMXF HRTX ADVM OCGN NKTR SGMO BDTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
RLMD:USA
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Website
https://www.relmada.com
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics (STU:4E2) Headlines

No Headlines